Topical Tacrolimus/Pimecrolimus Therapeutic Cheat Sheet
Tacrolimus and Pimecrolimus are both calcineurin inhibitors FDA-approved for atopic dermatitis. However, their topical use offers steroid-sparing benefits for a wide variety of other inflammatory dermatologic conditions. Tacrolimus was discovered in 1984 from the soil bacterium Streptomyces tsukubaensis and was originally FDA approved in 1994 as a systemic immunosuppressant for organ transplanta …
Tacrolimus and Pimecrolimus are both calcineurin inhibitors FDA-approved for atopic dermatitis. However, their topical use offers steroid-sparing benefits for a wide variety of other inflammatory dermatologic conditions. Tacrolimus was discovered in 1984 from the soil bacterium Streptomyces tsukubaensis and was originally FDA approved in 1994 as a systemic immunosuppressant for organ transplanta … Continue reading "Topical Tacrolimus/Pimecrolimus Therapeutic Cheat Sheet"
At the ODAC 2025 conference, Dr. Shawn Kwatra, Professor and Chair of Dermatology at the University of Maryland School of Medicine and a leading figure in chronic inflammatory skin diseases, delivered a compelling presentation on atopic dermatitis (AD). Dr. Kwatra provided an overview of current AD treatment options, along with valuable insights into the latest advancements emerging in the field o … 
Atopic dermatitis and prurigo nodularis are chronic, life-altering diseases with a common feature of debilitating pruritus that significantly impacts our patients’ qualities of life. For those with resistant and extensive disease, dermatologists now have nemolizumab in our armamentarium, the first FDA approved IL-31 inhibitor. We continue our series, Therapeutic Cheat Sheet, with a closer look a …